Precision Cardiology Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2024 - 2030)

Precision Cardiology Market Trends & Growth Drivers

Usage of AI-Driven Genomics Is Biggest Trend in Precision Medicine

• Most heart diseases have a genetic cause, whether inherited or acquired.
• This is why one of the first questions a doctor asks a patient is whether the latter has any history of heart disease in the family.
• This not only enables better risk assessment before the disease actually manifests but also allows for a more-precise and quicker diagnosis.
• With the increasing awareness of the role of genes in heart disease, the field of genomics is garnering significant interest.
• AI is being used in this field to establish better relations with patients’ genes and the heart disease they are most at risk for.
• NGS can be integrated with AI for a better understanding of DNA sequences, to enable the creation of targeted therapies.
• Moreover, with this, the clinical trial process can be sped up, which can lead to faster approvals for life-saving medicines around the world.

Increasing Prevalence of Heart Diseases Propels Market Growth

• Factors such as the geriatric population, sedentary lifestyle, unhealthy eating habits, diabetes, tobacco consumption, and family history of CVDs are some prominent risk factors imposing a combinatorial impact upon the high prevalence of CVDs.
• According to the Center for Disease Control and Prevention (CDC), almost 660,000 people in the U.S. die from heart disease each year.
• Moreover, as per the Heart Foundation, more than 4 million Australians have CVDs.
• In addition, according to the European Heart Network, CVDs cause 3.9 million deaths each year in Europe.
• Diagnostics is the first step toward reducing the incidence of CVDs.
• With the ever-evolving knowledge about molecular alterations associated with CVDs, including hereditary cardiac conditions, there is an urgent need for the identification of efficient and advanced diagnostic techniques for reducing the clinical burden caused by such diseases.
• Moreover, various end users, such as hospitals and diagnostic laboratories, are implementing molecular diagnostic tests for the assessment of CVDs to offer better clinical insights, further providing early treatment solutions.

High Cost of Technology Hampers Growth of Market

• Despite the rising incidence of advanced therapies for cardiac diseases, their uptake is limited around the world by their high costs.
• Next-generation NGS and gene editing kits, machines, and software are quite expensive, which makes the overall precision cardiology approach inaccessible to the market masses.
• Additionally, precision diagnostics and therapeutics require cutting-edge AI technologies, which further raises costs for both healthcare providers and patients.
• The integration of these advanced techniques into the existing healthcare infrastructure can also be challenging due to the lack of standardization of HIT protocols and additional training required for doctors and technicians.
• Further, such advanced healthcare fields are at a perpetual risk of regulatory compliance failures and fines and other repercussions, as a result.

Precision Cardiology Market Analysis

Offering Analysis

As of 2024, the precision cardiology market is dominated by the service category with a market share of around 70%. This bifurcation is also expected to witness the higher CAGR in the market, of 10.3%, during the forecast period.

This is primarily attributed to the rising emphasis on the adoption of precision medicine in clinical settings. Moreover, underlying factors, such as sedentary lifestyle, unhealthy diet, obesity, and the growing population of pre-diabetics and diabetics worldwide, are imposing a combinatorial effect upon the global burden of CVDs, which results in the rising precision diagnosis’ services demand.

The following offerings are covered in the report:

• Service (Larger and Faster-Growing Category)
• Product

Sample Analysis

The blood category dominates the market with 65% share in 2024. This is because blood is widely extracted from the body for routine disease analysis. Further, blood analysis allows for the swift discovery of precise biomarkers for assessing the severity of diseases, as well as determining the effectiveness of therapy. In addition, there are well-established protocols and methodologies for extracting, handling, processing, and analyzing blood, and the years of experience in hematology has made the process simpler and cost-effective.

The non-blood samples category is predicted to grow at the higher CAGR in the market during 2024–2030. This can be primarily due to the clinical utilities of non-blood samples, which have been well-established and documented for conducting precision tests. Moreover, the companies operating in the market are actively involved in developing advanced tests based on non-blood-based samples, such as saliva and buccal swab specimens, which, in turn, boost the sales of these samples.

The report offers analysis for the following samples:

• Blood (Larger Category)
• Non-Blood (Faster-Growing Category)
  • Saliva
  • Buccal swabs
  • Others

Technology Analysis

The sequencing category accounts for the highest revenue, in 2024. The category is also expected to witness the fastest growth in the coming years. This is due to its clinical advantages, including higher accuracy, low cost of sequencing, broader coverage, and high scalability. In particular, NGS provides large sets of critical data on DNA and genes, aided by technological advancements in analyzers and software. Moreover, this technique can be utilized to sequence the entire genome or exome, as well as to run genetic panels. To make it better, it is being integrated with ML, AI, and other advanced technologies, which is further expanding its scope of application.

We have analyzed the below-mentioned technologies:

• Sequencing (Largest and Fastest-Growing Category)
  • Next-generation sequencing (NGS)
  • Sanger sequencing
• Polymerase Chain Reaction (PCR)
• Microarray
• Others

Application Analysis

The cardiomyopathy application accounts for the largest share, of 45%, in 2024. This is attributed to the increasing global incidence of various types of cardiomyopathies, the rising focus on research for the development of novel molecular diagnostic solutions, and the surging adoption of precision medicines, among others. For instance, according to the American College of Cardiology, the global prevalence of alcoholic cardiomyopathy is over 700,000 cases.

The arrhythmia category will like grow the fastest over the forecast period. This is attributed to the increasing prevalence of abnormal heart rhythms, which can often be fatal if not treated in time. For instance, over 2.5 million people in the U.S. have atrial fibrillation, which can cause heart failure or stroke, if persistent and not addressed immediately. Ventricular fibrillation is another serious arrhythmia, and it is a common cause of sudden cardiac death. Arrhythmias can be difficult to predict as they have a variety of causes, from underlying heart conditions and genetic predisposition to obesity and electrolyte imbalance.

The following are the categories in the application segment:

• Cardiomyopathy (Largest Category)
• Arrhythmia (Fastest-Growing Category)
• Aortopathy and Vascular Diseases
• Familial Hypercholesterolemia (FH)
• Congenital Heart Defects and Syndromes
• Others

End User Analysis

Hospitals and diagnostic laboratories are the primary end users, with a share of 55%, in 2024. They are also predicted to witness the highest CAGR, of 10.5%, during the forecast period. Hospitals and diagnostic laboratories offer a wide range of expertise in pathology and advanced laboratory diagnostics for precision testing. These laboratories include state-of-the-art testing services required for conducting in-depth biomarker analysis with a strong foundation of consultation for various CVDs.

The report offers insights for the below-mentioned end users:

• Hospitals and Diagnostic Laboratories (Largest and Fastest-Growing Category)
• Academic and Research Institutes
• Others

Geographical Analysis

• In 2024, North America holds the largest revenue share in the precision cardiology market, of 40%.
• This is ascribed to the presence of major market players in the U.S. and the significant adoption of advanced products and services in clinical and research settings.
• Moreover, government initiatives targeting the correlation of genetic biomarkers with cardiovascular care have significantly propelled the overall market scenario in the region.
• Moreover, the U.S. Food and Drug Administration (FDA) and the Clinical Laboratory Improvement Amendments (CLIA) have played key roles in the development of effective and appropriate guidelines and policies for the adoption of precision medicinal products and services in the region.
• Further, with a highly dynamic market along with a consistently rising number of emerging companies offering end-to-end services, the North American market is likely to continue leading throughout the prediction period.
• The APAC region will be the fastest-growing market during the forecast period, with a CAGR of 4.8%.
• This is attributed to the increasing prevalence of heart diseases, growing aging population, rising rate of urbanization, adoption of unhealthy lifestyle habits, and increasing stress in people’s life due to peer pressure, financial problems, and other sociocultural factors.
• Not just the elderly, but even teenagers, young adults, and children are falling prey to heart diseases in the region.
• As per a February 2023 article in The Lancet, India has an age-standardized death rate of 282 deaths per 100,000 people from heart disease, which is higher than the global average of 233 deaths per 100,000 people.
• With the increasing number of patients, governments in regional countries are taking initiatives to advance their healthcare infrastructure and make medical care affordable for the masses.
• Encouraged by the strong support, healthcare institutions are integrating advanced genomics and AI methodologies into their cardiology departments, while private and public players are initiating research studies in this area.

The following regions and countries have been studied:

• North America (Largest Regional Market)
  • U.S. (Larger and Faster-Growing Country Market)
  • Canada
• Europe
  • Germany (Largest Country Market)
  • U.K. (Fastest-Growing Country Market)
  • Italy
  • France
  • Spain
  • Rest of Europe
• Asia-Pacific (APAC) (Fastest-Growing Regional Market)
  • China (Largest Country Market)
  • Japan
  • India (Fastest-Growing Country Market)
  • South Korea
  • Rest of APAC
• Latin America (LATAM)
  • Brazil (Largest Country Market)
  • Mexico (Fastest-Growing Country Market)
  • Rest of LATAM
• Middle East and Africa (MEA)
  • Saudi Arabia (Largest Country Market)
  • South Africa (Fastest-Growing Country Market)
  • Rest of MEA

Precision Cardiology Market Share

The precision cardiology market is consolidated, primarily because the field of healthcare is already technically demanding. The addition of genomics and AI technologies has further raised entry barriers for new companies. All this requires a high investment in R&D, which only large, well-financed companies can afford. Additionally, most established companies in the market are working in comprehensive partnerships with academic institutions, healthcare firms, and government agencies on R&D and clinical trials the field of precision medicine.

Precision Cardiology Market News

• In May 2024, CENTOGENE N.V. entered into a partnership with the Saudi Arabian PIF-owned biopharmaceutical company Lifera, under which the latter will invest around USD 20 million in CENTOGENE N.V.
• In February 2024, Eurofins Scientific launched its DiscoveryAI SAFIRE platform, which uses ML, AI, and proprietary datasets to better predict the absorption, distribution, metabolism, excretion and toxicity (ADMET) properties of drug molecules.
• In January 2022, GENinCode, one of the emerging predictive genetics companies, filed a pre-submission application to the FDA for its new Cardio inCode-SCORE. Cardio inCode-SCORE is an IVD test that assesses an individual's combined genetic and clinical risks for predicting and preventing CVDs.
• In January 2022, DNA Genotek Inc., a wholly-owned subsidiary of OraSure Technologies Inc., announced that it had received a general use 510(k) clearance from the U.S. FDA for its Oragene•Dx family of products. The Oragene•Dx products, including ORAcollect•Dx Saliva Swab Collection Kit, are being widely used by service providers offering cardiovascular genetic tests.